ClinicalTrials.gg
RecruitingNCT06484244Updated Mar 2, 2026

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

An interventional study of 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation in Alzheimers Disease and Mild Cognitive Impairment, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alzheimer Disease by Emory University — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Emory University.

Planned enrollment
22nd of 25
10 · median 50
Started
2025
with 1 other
No phase
19 of 28
5 open now
Registered
25th of 28
by date

Among the 28 studies in Alzheimer Disease by Emory University, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 19 with no phase, and was the 25th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 28 studies in Alzheimer Disease by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Emory University, or all of them as a file.
02

Study summary

In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.

Read the detailed description

In conjunction with cognitive impairments, older adults with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) show increased impairments in walking function throughout disease progression. The ability to walk without the risk of falling is necessary for independent community activity and participation for elderly individuals. However, the relationships between cognition, gait dysfunction, and fall risk in people with MCI and AD are poorly understood, warranting further study. The objective of this study is to test the researchers' central hypothesis that in people with MCI and AD, decreased capacity for locomotor adaptation can worsen disease progression, and lead to reduced motor-cognitive function, mobility, and quality of life.

Community-based walking function requires complex motor coordination, sensory feedback, dynamic balance, adaptation to changing environmental stimuli, while also engaging in attentional tasks such as crossing a busy street or talking over the phone. Unfortunately, cognitive dysfunction, the hallmark of MCI and AD, directly impacts the cognitive-motor neural resources needed to carry out activities of daily living. People with MCI and AD walk slower, fall more, and have deficits in gait performance variables such as stride symmetry, and step regularity. Importantly, gait disturbances have often been shown to precede cognitive decline. In this study, the researchers propose to test their hypothesis that a decline in locomotor adaptation capacity may explain gait and mobility deficits in people with MCI and AD. Locomotor adaptation is a fundamentally important process that enables humans to flexibility respond to environmental demands, enabling normal community walking function. Split-belt adaptation is a standardized, robust, well studied paradigm for quantifying a person's capacity for locomotor adaptation, but had not yet been evaluated in people with MCI and AD. Split-belt walking task assesses locomotor adaptation, i.e. the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. The split-belt task is systematically assessed during treadmill walking, where the speed of each leg can be controlled independently such that one belt and the corresponding leg run at a different speed (e.g., twice as fast or a 2:1 speed ratio) than the other leg. In previous work, both the magnitude and rate of split-belt adaptation as well as de-adaptation (during the after-effect) have provided objective measures of an individual's locomotor adaptation capacity.

The researchers of this study hypothesize that decreased capacity for split-belt adaptation may be an important contributing factor and a potentially sensitive indicator of increased fall risk and cognitive decline in older individuals with MCI and AD.

The researchers will examine locomotor adaptation capacity with three study aims: Aims 1 and 2 are observational, assessing walking function among persons with MCI and AD and age-matched controls. In Aim 3, a clinical trial is performed to evaluate the feasibility of a split-belt walking intervention on walking function in older adults with MCI and AD. Ten participants (5 with MCI and 5 with AD) will complete 5 split-belt treadmill walking exercise sessions over a 2-week period. The primary and secondary outcome measures for this study are measured in evaluation sessions before (Pre-training) and after 5 training sessions (Post-training).

03

Conditions studied

  • Alzheimers Disease
  • Mild Cognitive Impairment

Keywords

  • walking function
  • gait disturbances
  • gait variability
  • locomotor adaptation
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD and MCI will be defined through formal diagnosis provided by a board-certified Neurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnestic subtype defined as:

    • Subjective memory concern or a memory problem noted by their partner
    • Abnormal memory function documented by a specified education adjusted cutoff score on the delayed paragraph recall of the Anna Thompson story of the Logical Memory subtest from the Wechsler Memory Scale-Revised
    • (MMSE) score between 20 and 26 (inclusive). Exceptions may be made for subjects with less than 8 years of education at the discretion of the PI. (iv) Single or multi-domain amnestic MCI (both subtypes are at high risk for progression to AD)
    • Clinical Dementia Rating (CDR) = 0.5 (Memory Box score must be at least 0.5)
    • General functional performance sufficiently preserved
  • Evidence of impaired executive function based on Montreal Cognitive Assessment (MoCA) score 13-17
  • Able to walk 10 or more feet without an assistive device
  • Completed six grades of education or has a good work history (sufficient to exclude intellectual disabilities)
  • Not hospitalized within the last 60 days

Exclusion criteria

Exclusion Criteria:

  • Acute medical illness requiring hospitalization
  • Uncontrolled congestive heart failure
  • History of stroke
  • Inability to perform study procedures
  • Medical or physical conditions that would preclude participation or walking (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity)
  • On medications that could adversely affect cognition, eg: antipsychotics, opioids, stimulants, chemotherapy, anti-parkinsonian drugs (eg Levodopa), neurologic prescriptions to treat Multiple sclerosis and/or Parkinson's
  • Psychotic disorders
  • Confounding neurologic conditions (e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae)
  • Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Split-beltTreadmill-based Locomotor Adaptation in Older Adults with MCI

    Older adults with mild cognitive impairment (MCI) complete 5 split-belt treadmill walking exercise sessions over a 2-week period.

    Other: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation

  • Experimental
    Split-beltTreadmill-based Locomotor Adaptation in Older Adults with AD

    Older adults with Alzheimer's Disease (AD) complete 5 split-belt treadmill walking exercise sessions over a 2-week period.

    Other: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation

Interventions

  • Other5 Sessions of Split-belt Treadmill-based Locomotor Adaptation

    Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).

06

What researchers measure

Primary outcomes

  1. Change in Adaptation Magnitude Assessed as Peak Step Length Symmetry

    Locomotor adaptation is the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. Step length symmetry data from the split-belt phase will be used to evaluate each individual's locomotor adaptation magnitude capacity by assessing the peak step length symmetry in the early adaptation period.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  2. Change in Adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry

    The adaptation rate is assessed as the number of steps required to reach a plateau in step symmetry during late adaptation.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  3. Change in 10-Meter Overground Walk Test

    Gait speed is assessed with the 10-Meter Overground Walk Test. The 10-Meter Overground Walk Test is used to assess walking speed over a short distance. A 10 meter (m) walkway over solid flooring will be measured and marked at start (0 m), 2 m, 8 m, and finish (10 m). Participants will be asked to complete three trials of the 10 m walk at their comfortable self-selected walking speed. The time for the three trials for each speed will be averaged and gait speed converted to meters/second.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  4. Change in 6-Minute Walk Test

    Gait endurance is assessed with the 6-minute walk test. The 6-Minute Walk Test is a sub-maximal exercise test used to assess walking endurance. A walkway of a minimum 12 m over solid flooring will be measured and marked with a turn-around marked at either end of the walkway. The turn-around points will be approximately 49 inches (124 cm) wide with clear markings. A chair will be placed at one end of the walkway to allow for seated rest breaks if necessary. Prior to administering the test, the participant will be seated in the chair resting. The participant will then be asked to walk as far as possible in 6 minutes along the walkway using scripted instruction (see below). The distance (in meters) will be calculated by multiplying the number of total laps by 12 meters and adding the distance of the partial lap completed at the time the test ended.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  5. Change in Montreal Cognitive Assessment (MoCA) Score

    MoCA is an instrument to screen for mild cognitive dysfunction, assessing the cognitive domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total scores range from 0 to 30 with higher scores indicating better cognitive function. A normal score is considered to be 26 or higher.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  6. Change in NIH-EXAMINER n-back Task Accuracy

    The NIH-EXAMINER assesses spatial working memory with the n-back tasks. The 1-back involves maintaining and updating one location at a time while two locations at a time are maintained and updated with the 2-back. During the n-back tasks, participants view a series of stimuli and press a button when a particular stimulus has been previously shown. The 1-back consists of one block of 30 trials, ten of which match the location of the previous square, and 20 that are in a different location. The 2-back consists of one block of 90 trials, 30 of which match the location of the square two before, and 60 that are in a different location. The score is calculated as the percentage of correct responses.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

Secondary outcomes

  1. Change in De-adaptation Magnitude Assessed as Peak Step Length Symmetry

    Step length symmetry data from the split-belt phase will be used to evaluate each individual's locomotor de-adaptation magnitude capacity by assessing the peak step length symmetry after treadmill belt speeds return to normal.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  2. Change in De-adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry

    The de-adaptation rate is assessed as the number of steps required to reach a plateau in step symmetry after treadmill belt speeds return to normal.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  3. Change in Timed Up and Go (TUG) Test

    The Timed Up and Go test assesses mobility, balance, walking ability, and fall risk in older adults. The participant will be asked to be seated in a standard height chair (seat height 46 cm, arm height 67 cm), placing his/her back against the chair and resting his/her arms on the chair's arms. The participant will be asked to get up from the chair, walk to a line 3 m from the edge of the chair, turn around at the line, walk back to the chair, and sit down. The test will be timed using a stopwatch from when the investigator says "Go" to when the participant's buttocks touches the chair upon return. Time of the test will be recorded for single and dual-task conditions.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  4. Change in Falls History

    Falls incidence and risk is assessed as self-reported history of falls.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  5. Change in Stride Duration

    Gait performance is assessed as gait cycle duration, which is the time in milliseconds (ms) for the same foot to contact the floor in consecutive footsteps.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  6. Change in Double-support Duration

    Gait performance is assessed as double-support duration. Double-support is the time when both feet are contacting the ground and it increases as walking speed decreases.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  7. Change in Executive Index Score (EIS)

    Cognition is assessed with the Executive Index Score (EIS) which is based on performance on Trail-Making Test Part B, Clock Drawing, Digit Span, Letter A Tapping, Serial 7 Subtraction, Letter Fluency and Abstraction items. The EIS is calculated by adding raw scores for the included tasks. Total scores range from 0 to 13 and higher scores indicate better cognitive function.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  8. Change in Trail Making Test Part B Score

    In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  9. Change in Step Length

    Gait performance is assessed with step length. Step length is the distance between heel of one foot to the heel print of the other foot, measured in feet.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

  10. Change in Step Length Variability

    Gait performance is assessed with the variability of step length.

    Time frame: Baseline (Pre-training), Week 2 (Post-training)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified demographic, clinical measures of walking and sensorimotor function, walking biomechanics, and electromyography (EMG) data that is collected during this study will be made available for sharing with the research community. All preprocessed data will be deposited to Distributed Archives for Neurophysiology Data Integration (DANDI) after the conclusion of the award period for this study.

Supporting information: Analytic code

Time frame: The research community will have access to the data when the award for this study ends and findings from this study are published. The data will be preserved indefinitely and is subject to decisions by DANDI regarding how long data will be preserved.

Access criteria: The research community will have unrestricted access to the data with an account through DANDI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 17 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Jul 22, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06484244
Lead sponsor
Emory University
Responsible party
Trisha Kesar (Associate Professor, Emory University) — Principal investigator
First posted
Jul 3, 2024
Start date
Jul 22, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Trisha Kesar, PT, PhD
Contact
tkesar@emory.edu
(404) 712-5803
Trisha Kesar, PT, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion